false
0000073290
0000073290
2026-10-09
2026-10-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 9, 2026
BIOMERICA,
INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-37863 |
|
95-2645573 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
| 17571
Von Karman Ave. Irvine, California |
|
92614 |
| (Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (949) 645-2111
Not
Applicable
(Former
name or former address if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.08 |
|
BMRA |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
October 12, 2026, David Moatazedi, a member of the Board of Directors (the “Board”) of Biomerica, Inc. (the “Company”),
communicated to the Board that he has determined not to stand for re-election to the Board at the Company’s 2026 Annual Meeting
of the Stockholders, which is set for December 11, 2026. Mr. Moatazedi serves on the Nominating and Corporate Governance Committee and
the Audit Committee of the Board and as Chairperson of the Compensation Committee of the Board. Mr. Moatazedi’s decision not to
stand for re-election was not the result of any dispute or disagreement with the Company or the Board. Mr. Moatazedi has served on the
Board since December 2022. The Company thanks Mr. Moatazedi for his dedicated service to the Company.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
BIOMERICA,
INC. |
| |
|
|
| Date:
October 15, 2026 |
By: |
/s/
Zackary S. Irani |
| |
|
Zackary
S. Irani
|
| |
|
Chief
Executive Officer |
